ERBB2 and breast carcinoma: Our previous study showed that HER2 overexpression was able to downregulate expression of the RBM5 splices variant RBM5 + 5 + 6 in breast cancer cells [19], moreover, RBM5 is downregulated by the constitutively activated RAS mutant protein, RAS(G12V), in rat embryonic fibroblast cells [20], which indicates a correlation between the EGFR and RAS pathways and RBM5 expression.